Control of cell cycle progression in human mesothelioma cells treated with gamma interferon

被引:29
作者
Vivo, C
Lévy, F
Pilatte, Y
Fleury-Feith, J
Chrétien, P
Monnet, I
Kheuang, L
Jaurand, MC
机构
[1] Univ Paris 12, INSERM U99 09, EA 2345, F-94010 Creteil, France
[2] Hop Tenon, Serv Histol & Biol Tumorale, F-75020 Paris, France
[3] Ctr Hosp Intercommunal, Serv Immunohematol, F-94010 Creteil, France
[4] Ctr Hosp Intercommunal, Serv Pneumol, F-94010 Creteil, France
关键词
human mesothelioma cell lines; cell cycle control; cyclin dependent kinase inhibitors; cyclin; r-hu-IFN gamma;
D O I
10.1038/sj.onc.1204199
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recombinant human interferon gamma (r-hu-IFN gamma) exerts both antitumoral activity in the early stages of human malignant mesothelioma and a cytostatic effect in human mesothelioma (HM) cell lines in vitro. The antiproliferative effect of interferons (IFNs) reported in a variety of cells has been attributed to several mechanisms. In order to progress in the understanding of HM cell growth modulation by r-hu-IFN gamma, modifications of cell cycle progression and expression of key cell cycle regulator proteins in response to r-hu-IFN gamma were examined. Nine HM cell lines were studied, including one resistant to the antiproliferative effect of r-hu-IFN gamma. Except in the resistant cell line r-hu-IFN gamma produced an arrest in the G1 and G2-M phases of the cell cycle, associated with a reduction in both cyclin A and cyclin dependent kinase inhibitors (CDKIs) expression. Moreover cyclin B1/cdc2 activity was decreased. The present study provides the first evidence of a GZ-arrest in r-hu-IFN gamma -treated HM cell lines and indicates that HM cell lines, despite their tumorigenic origin still support cell cycle control. The cell cycle arrest induced by r-hu-IFN gamma seems to depend on cyclin regulation through p21(WAF1/C1P1)- and p27(KiP1)-independent mechanisms and is not directly related to the induced DNA damage.
引用
收藏
页码:1085 / 1093
页数:9
相关论文
共 54 条
[1]  
Astoul P, 1998, CANCER, V83, P2099, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO
[2]  
2-3
[3]   NUCLEAR ACCUMULATION OF INTERFERON-GAMMA [J].
BADER, T ;
WIETZERBIN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (25) :11831-11835
[4]   INTERLEUKIN-6 INVOLVEMENT IN MESOTHELIOMA PATHOBIOLOGY - INHIBITION BY INTERFERON-ALPHA IMMUNOTHERAPY [J].
BIELEFELDTOHMANN, H ;
MARZO, AL ;
HIMBECK, RP ;
JARNICKI, AG ;
ROBINSON, BWS ;
FITZPATRICK, DR .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1995, 40 (04) :241-250
[5]   POTENTIAL FOR INTERFERON-ALPHA-BASED THERAPY IN MESOTHELIOMA - ASSESSMENT IN A MURINE MODEL [J].
BIELEFELDTOHMANN, H ;
FITZPATRICK, DR ;
MARZO, AL ;
JARNICKI, AG ;
MUSK, AW ;
ROBINSON, BWS .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1995, 15 (03) :213-223
[6]   Cellular responses to interferon-gamma [J].
Boehm, U ;
Klamp, T ;
Groot, M ;
Howard, JC .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :749-795
[7]  
BOUTIN C, 1994, CANCER, V74, P2460, DOI 10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO
[8]  
2-N
[9]   CHEMOSENSITIVITY AND CYTOKINE SENSITIVITY OF MALIGNANT MESOTHELIOMA [J].
BOWMAN, RV ;
MANNING, LS ;
DAVIS, MR ;
ROBINSON, BWS .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (06) :420-426
[10]   Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma [J].
Bromberg, JF ;
Horvath, CM ;
Wen, ZL ;
Schreiber, RD ;
Darnell, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) :7673-7678